Daniel J. Odenheimer
Profile
Daniel J.
Odenheimer worked as a Director of US Clinical Research at Ligand UK Ltd.
and as a Director of Department of Clinical Research at Boehringer Mannheim Pharmaceuticals Corp.
He also served as Vice President of Clinical Development and Evaluation at Human Genome Sciences, Inc. and as Vorstand Klinikalforschungs at Roche Diagnostics GmbH.
Odenheimer received his undergraduate and graduate degrees from the University of California, Berkeley and his graduate and doctorate degrees from the University of Michigan.
Former positions of Daniel J. Odenheimer
| Companies | Position | End |
|---|---|---|
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Chief Tech/Sci/R&D Officer | 01/01/2013 |
| VERNALIS | Corporate Officer/Principal | - |
| Boehringer Mannheim Pharmaceuticals Corp. | Corporate Officer/Principal | - |
Roche Diagnostics GmbH
 Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Chief Tech/Sci/R&D Officer | - |
Training of Daniel J. Odenheimer
| University of Michigan | Doctorate Degree |
| University of California, Berkeley | Graduate Degree |
Experiences
Positions held
Linked companies
| Private companies | 4 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Roche Diagnostics GmbH
Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Commercial Services |
| Boehringer Mannheim Pharmaceuticals Corp. | |
Ligand UK Ltd.
 Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Daniel J. Odenheimer
